Qin Xiaohan, Li Tianhao, Sun Wei, Guo Xiaoxiao, Fang Quan
Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ther Adv Chronic Dis. 2021 Sep 26;12:20406223211047304. doi: 10.1177/20406223211047304. eCollection 2021.
Pulmonary arterial hypertension (PAH) is a rare but fatal cardiovascular disorder with high morbidity and mortality. Diagnosis and treatment of this disease at an early stage would greatly improve outcomes. The molecular indicators of PAH are mostly nonspecific, and diagnostic and prognostic biomarkers are urgently needed. A more comprehensive understanding of the molecular mechanisms underlying this complex disease is crucial for the development of new and more effective therapeutics to improve patient outcomes. In this article, we review published literature on proteomic biomarkers and underlying molecular mechanisms in PAH and their value for disease management, aiming to deepen our understanding of the disease and, ultimately, pave the way for clinical application.
肺动脉高压（PAH）是一种罕见但致命的心血管疾病，发病率和死亡率都很高。早期诊断和治疗这种疾病将大大改善预后。PAH的分子指标大多是非特异性的，迫切需要诊断和预后生物标志物。更全面地了解这种复杂疾病的分子机制对于开发新的、更有效的治疗方法以改善患者预后至关重要。在本文中，我们综述了已发表的关于PAH中蛋白质组学生物标志物及其潜在分子机制以及它们在疾病管理中的价值的文献，旨在加深我们对该疾病的理解，并最终为临床应用铺平道路。
